Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a specific set of four pharmacological agents—caffeine, paracetamol (acetaminophen), cephalexin, and ibuprofen—utilized in a clinical trial conducted by the King Faisal Specialist Hospital & Research Center. The study (NCT02444429) investigated whether the placebo effect, or the psychological expectation of receiving a drug, modulates the bioavailability and pharmacokinetics of these substances. Caffeine acts as a central nervous system stimulant; paracetamol is an analgesic and antipyretic; cephalexin is a first-generation cephalosporin antibiotic; and ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). The trial used these drugs as models to explore the interaction between psychological expectation and drug metabolism, specifically testing if the placebo effect could prolong drug half-life or alter absorption profiles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + paracetamol + cephalexin + ibuprofen.